Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%

Schering-Plough is seeing most of the early use of Zetia in either high-risk or statin-intolerant patients, Global Pharmaceuticals President Carrie Cox told investors during a quarterly earnings call Oct. 22